Rezolute Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Rezolute wird ein Gewinn- und Umsatzwachstum von 52.4% bzw. 69.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 53.5% pro Jahr wachsen soll.

Wichtige Informationen

52.4%

Wachstumsrate der Gewinne

53.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	69.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	12 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

May 22

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Feb 13

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Sep 21

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

Jan 12

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:RZLT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2027	48	-73	-39	-102	7
6/30/2026	5	-88	-65	-77	10
6/30/2025	N/A	-69	-79	-90	10
9/30/2024	N/A	-69	-63	-63	N/A
6/30/2024	N/A	-68	-57	-57	N/A
3/31/2024	N/A	-58	-50	-50	N/A
12/31/2023	N/A	-57	-53	-53	N/A
9/30/2023	N/A	-56	-48	-47	N/A
6/30/2023	N/A	-52	-45	-44	N/A
3/31/2023	N/A	-48	-45	-45	N/A
12/31/2022	N/A	-44	-41	-41	N/A
9/30/2022	N/A	-43	-41	-41	N/A
6/30/2022	N/A	-41	-40	-40	N/A
3/31/2022	N/A	-38	-33	-33	N/A
12/31/2021	N/A	-31	-24	-24	N/A
9/30/2021	N/A	-25	-23	-23	N/A
6/30/2021	N/A	-21	-20	-20	N/A
3/31/2021	N/A	-18	-19	-19	N/A
12/31/2020	N/A	-19	-20	-20	N/A
9/30/2020	N/A	-19	-19	-19	N/A
6/30/2020	N/A	-20	-24	-24	N/A
3/31/2020	N/A	-20	-24	-24	N/A
12/31/2019	N/A	-37	-27	-27	N/A
9/30/2019	N/A	-34	-23	-23	N/A
6/30/2019	N/A	-33	-15	-15	N/A
3/31/2019	N/A	-42	-15	-15	N/A
12/31/2018	N/A	-25	-9	-9	N/A
9/30/2018	N/A	-27	-11	-11	N/A
6/30/2018	N/A	-30	N/A	-14	N/A
3/31/2018	N/A	-24	N/A	-14	N/A
12/31/2017	N/A	-27	N/A	-15	N/A
9/30/2017	N/A	-27	N/A	-15	N/A
6/30/2017	N/A	-24	N/A	-13	N/A
3/31/2017	N/A	-27	N/A	-13	N/A
12/31/2016	N/A	-22	N/A	-12	N/A
9/30/2016	N/A	-21	N/A	-11	N/A
6/30/2016	N/A	-21	N/A	-10	N/A
3/31/2016	N/A	-14	N/A	-9	N/A
12/31/2015	N/A	-14	N/A	-9	N/A
9/30/2015	N/A	-12	N/A	-8	N/A
6/30/2015	N/A	-11	N/A	-7	N/A
3/31/2015	N/A	-10	N/A	-7	N/A
12/31/2014	N/A	-12	N/A	-6	N/A
9/30/2014	N/A	-11	N/A	-5	N/A
6/30/2014	N/A	-10	N/A	-3	N/A
3/31/2014	N/A	-9	N/A	-1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RZLT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: RZLT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: RZLT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: RZLTDie Einnahmen des Unternehmens (69.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: RZLTDie Einnahmen des Unternehmens (69.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von RZLT in 3 Jahren voraussichtlich hoch sein wird

Rezolute Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 7.5% to US$12.78

Price target increased by 7.2% to US$12.75

Consensus EPS estimates upgraded to US$0.98 loss

Price target increased by 8.1% to US$11.89

Price target increased by 9.4% to US$10.57

Price target increased by 9.0% to US$8.50

Recent updates

Price target increased by 7.5% to US$12.78

Rezolute, Inc., Annual General Meeting, Dec 05, 2024

Price target increased by 7.2% to US$12.75

Consensus EPS estimates upgraded to US$0.98 loss

Insufficient new directors

Price target increased by 8.1% to US$11.89

New major risk - Shareholder dilution

Rezolute, Inc. Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute, Inc. announced that it expects to receive $6 million in funding

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $59.99625 million.

New major risk - Share price stability

Price target increased by 9.4% to US$10.57

Rezolute, Inc. Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

Rezolute, Inc., Annual General Meeting, May 16, 2024

Director recently bought US$70k worth of stock

Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Chief Financial Officer recently bought US$67k worth of stock

Price target increased by 9.0% to US$8.50

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Now 29% overvalued after recent price rise

Rezolute, Inc. Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute, Inc. Appoints Daron Evans as Chief Financial Officer

Rezolute, Inc. Announces Completion of Enrollment in its RZ402 Phase 2 Study in Diabetic Macular Edema

Rezolute Receives a Written Notice from the Listing Qualifications Department of Nasdaq Stock Market

New minor risk - Shareholder dilution

New minor risk - Share price stability

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation

New major risk - Revenue and earnings growth

Price target decreased by 30% to US$7.80

Rezolute, Inc. Provides an Update on Its Clinical Development Plans for RZ358

Rezolute, Inc. to Report Q3, 2023 Results on May 11, 2023

Price target decreased by 7.9% to US$11.60

We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

Rezolute, Inc. Announces Initiation of A Phase 2 Study of Rz402 in Patients with Diabetic Macular Edema

High number of new and inexperienced directors

Price target decreased to US$12.60

Rezolute GAAP EPS of -$0.37

Rezolute, Inc. Promotes Brian Roberts to Chief Medical Officer

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Price target decreased to US$19.20

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $117.587085 million.

Rezolute, Inc. Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism

Rezolute, Inc., Annual General Meeting, Jun 30, 2022

High number of new and inexperienced directors

Rezolute, Inc Announces Positive Study Results for RZ402, an oral PKI being developed for DME

Rezolute, Inc. Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies At ESPE 2021

Rezolute, Inc. Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism

Rezolute, Inc. Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME

Price target decreased to US$26.50

High number of new and inexperienced directors

Price target decreased to US$27.00

We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate

Rezolute, Inc. Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema

Rezolute shares rise on positive topline results from RZ402 eye disease trial

Rezolute, Inc. Announces Board Appointments

New 90-day low: US$11.98

Rezolute, Inc. Announces Phase 2B Study of RZ358 Continues to Enroll Congenital Hyperinsulinism (HI) Patients Worldwide

Rezolute Announces Initiation of Phase 1 Study of RZ402 for the Treatment of Diabetic Macular Edema

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

New 90-day low: US$12.94

Rezolute, Inc. Announces Resignation of Jung-Hee Lim as a Member of the Board of Directors, Audit Committee and Compensation Committee

Price target raised to US$31.50

Rezolute, Inc. Announces CFO Changes

Rezolute, Inc. announced that it expects to receive $40.92 million in funding from BVF Partners LP, Citadel Advisors LLC, and other investors

Rezolute, Inc. announced delayed annual 10-K filing

Rezolute Announces Publication of Rz402 Data in Diabetic Macular Edema (Dme) in Investigative Ophthalmology & Visual Science